{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:38:23Z","timestamp":1782236303632,"version":"3.54.5"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chest"],"published-print":{"date-parts":[[2004,1]]},"DOI":"10.1378\/chest.125.1.249","type":"journal-article","created":{"date-parts":[[2004,1,13]],"date-time":"2004-01-13T00:28:25Z","timestamp":1073953705000},"page":"249-259","source":"Crossref","is-referenced-by-count":156,"title":["The Role of Long-Acting Bronchodilators in the Management of Stable COPD"],"prefix":"10.1016","volume":"125","author":[{"given":"Donald P.","family":"Tashkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1378\/chest.125.1.249_bib1","doi-asserted-by":"crossref","first-page":"187S","DOI":"10.1378\/chest.107.5_Supplement.187S","article-title":"Issues concerning health-related quality of life","volume":"107","author":"Jones","year":"1995","journal-title":"Chest"},{"key":"10.1378\/chest.125.1.249_bib2","first-page":"A642","article-title":"Costs of COPD exacerbations [abstract]","volume":"163","author":"Oostenbrink","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.125.1.249_bib3","series-title":"World Health Report 2000. Health systems: improving performance. Annex table 3","year":"2000"},{"key":"10.1378\/chest.125.1.249_bib4","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1164\/ajrccm.163.5.2101039","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI\/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary","volume":"163","author":"Pauwels","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.125.1.249_bib5","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1378\/chest.115.4.957","article-title":"Efficacy of salmeterol xinafoate in the treatment of COPD","volume":"115","author":"Mahler","year":"1999","journal-title":"Chest"},{"key":"10.1378\/chest.125.1.249_bib6","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1183\/09031936.97.10040815","article-title":"An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)","volume":"10","author":"Boyd","year":"1997","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.125.1.249_bib7","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1164\/ajrccm.155.4.9105068","article-title":"Quality of life changes in COPD patients treated with salmeterol","volume":"155","author":"Jones","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.125.1.249_bib8","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1378\/chest.96.5.984","article-title":"Cholinergic bronchomotor tone in COPD: estimates of its amount in comparison with that in normal subjects","volume":"96","author":"Gross","year":"1989","journal-title":"Chest"},{"key":"10.1378\/chest.125.1.249_bib9","series-title":"Managing chronic obstructive pulmonary disease","first-page":"1","author":"Barnes","year":"1999"},{"key":"10.1378\/chest.125.1.249_bib10","series-title":"Chronic obstructive pulmonary disease","first-page":"391","article-title":"Bronchodilators: basic pharmacology","author":"Barnes","year":"1995"},{"key":"10.1378\/chest.125.1.249_bib11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0306-3623(88)90021-3","article-title":"\u03b2-Adrenoceptor function in asthmatic bronchial smooth muscle","volume":"19","author":"Lulich","year":"1988","journal-title":"Gen Pharmacol"},{"key":"10.1378\/chest.125.1.249_bib12","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1378\/chest.105.5.1411","article-title":"In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial","volume":"105","author":"Combivent Aerosol Study Group","year":"1994","journal-title":"Chest"},{"key":"10.1378\/chest.125.1.249_bib13","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0024-3205(93)90310-Y","article-title":"Muscarinic receptor subtypes in airways","volume":"52","author":"Barnes","year":"1993","journal-title":"Life Sci"},{"key":"10.1378\/chest.125.1.249_bib14","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/S0024-3205(01)01052-9","article-title":"Antimuscarinic treatment for lung diseases from research to clinical practice","volume":"68","author":"Disse","year":"2001","journal-title":"Life Sci"},{"key":"10.1378\/chest.125.1.249_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1046\/j.1365-2222.1999.00010.x","article-title":"Interaction of viral infections with muscarinic receptors","volume":"29","author":"Jacoby","year":"1999","journal-title":"Clin Exp Allergy"},{"key":"10.1378\/chest.125.1.249_bib16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1183\/09031936.98.11010086","article-title":"Effect of salmeterol onHaemophilus influenzae infection of respiratory mucosain vitro","volume":"11","author":"Dowling","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.125.1.249_bib17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1034\/j.1399-3003.1999.14b21.x","article-title":"Effect of fluticasone propionate and salmeterol onPseudomonas aeruginosa infection of the respiratory mucosain vitro","volume":"14","author":"Dowling","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.125.1.249_bib18","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1378\/chest.120.1.258","article-title":"Alternative mechanisms for long-acting \u03b22-adrenergic agonists in COPD","volume":"120","author":"Johnson","year":"2001","journal-title":"Chest"},{"key":"10.1378\/chest.125.1.249_bib19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1183\/09031936.02.00269802","article-title":"A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease","volume":"19","author":"Casaburi","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.125.1.249_bib20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1183\/09031936.02.00238702","article-title":"Improved health outcomes in patients with COPD during 1 yr treatment with tiotropium","volume":"19","author":"Vincken","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.125.1.249_bib21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1378\/chest.122.1.47","article-title":"A 6-month placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol","volume":"122","author":"Donohue","year":"2002","journal-title":"Chest"},{"key":"10.1378\/chest.125.1.249_bib22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/thorax.58.5.399","article-title":"Health outcomes in a 6-month placebo controlled trial of once-daily tiotropium compared with twice-daily salmeterol in patients with COPD","volume":"58","author":"Brusasco","year":"2003","journal-title":"Thorax"},{"key":"10.1378\/chest.125.1.249_bib23","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1183\/09031936.02.00240902","article-title":"Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial","volume":"19","author":"Aalbers","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.125.1.249_bib24","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1164\/ajrccm.164.5.2007006","article-title":"Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease","volume":"164","author":"Dahl","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.125.1.249_bib25","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1378\/chest.121.4.1058","article-title":"Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD","volume":"121","author":"Rossi","year":"2002","journal-title":"Chest"},{"key":"10.1378\/chest.125.1.249_bib26","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1378\/chest.119.5.1347","article-title":"In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3-week, randomized, double-blind, within-patient, multicenter study","volume":"119","author":"D'Urzo","year":"2001","journal-title":"Chest"},{"key":"10.1378\/chest.125.1.249_bib27","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1183\/09031936.03.00031402","article-title":"Efficacy and safety of budesonide\/formoterol in the management of chronic obstructive disease","volume":"21","author":"Szafranski","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.125.1.249_bib28","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1164\/ajrccm.163.5.9903053","article-title":"Use of a long-acting inhaled \u03b22-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease","volume":"163","author":"Rennard","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.125.1.249_bib29","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1034\/j.1399-3003.2000.15e11.x","article-title":"Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium","volume":"15","author":"van Noord","year":"2000","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.125.1.249_bib30","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/thx.54.11.995","article-title":"An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting","volume":"54","author":"Rutten-van M\u00f6lken","year":"1999","journal-title":"Thorax"},{"key":"10.1378\/chest.125.1.249_bib31","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1155\/2002\/493296","article-title":"The addition of salmeterol 50 \u03bcg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial","volume":"9","author":"Chapman","year":"2002","journal-title":"Can Respir J"},{"key":"10.1378\/chest.125.1.249_bib32","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1378\/chest.119.6.1661","article-title":"Salmeterol plus theophylline combination therapy in the treatment of COPD","volume":"119","author":"ZuWallack","year":"2001","journal-title":"Chest"},{"key":"10.1378\/chest.125.1.249_bib33","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1378\/chest.118.6.1576","article-title":"Additive effects of salmeterol and fluticasone or theophylline in COPD","volume":"118","author":"Cazzola","year":"2000","journal-title":"Chest"},{"key":"10.1378\/chest.125.1.249_bib34","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.2112055","article-title":"Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease","volume":"166","author":"Mahler","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.125.1.249_bib35","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(03)12459-2","article-title":"Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial","volume":"361","author":"Calverley","year":"2003","journal-title":"Lancet"},{"key":"10.1378\/chest.125.1.249_bib36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1155\/2002\/604092","article-title":"Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study","volume":"9","author":"Kottakis","year":"2002","journal-title":"Can Respir J"},{"key":"10.1378\/chest.125.1.249_bib37","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1053\/rmed.2001.1161","article-title":"Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk)","volume":"95","author":"Benhamou","year":"2001","journal-title":"Respir Med"},{"key":"10.1378\/chest.125.1.249_bib38","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1378\/chest.110.1.62","article-title":"Extended therapy with ipratropium is associated with improved lung function in patients with COPD: a retrospective analysis of data from seven clinical trials","volume":"110","author":"Rennard","year":"1996","journal-title":"Chest"},{"key":"10.1378\/chest.125.1.249_bib39","first-page":"25","article-title":"Understanding dyspnoea in COPD [abstract]: mechanisms, measurement and management","volume":"12","author":"Harver","year":"2002","journal-title":"Eur Respir Rev"},{"key":"10.1378\/chest.125.1.249_bib40","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1378\/chest.85.6.751","article-title":"The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes","volume":"85","author":"Mahler","year":"1984","journal-title":"Chest"},{"key":"10.1378\/chest.125.1.249_bib41","first-page":"A266","article-title":"Validity and patterns of response of dyspnea measures in a 6 month bronchodilator intervention trial in COPD [abstract]","volume":"165","author":"Witek","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.125.1.249_bib42","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1053\/rmed.2001.1335","article-title":"Effects of formoterol (Oxis Turbuhaler) and ipratropium on exercise capacity in patients with COPD","volume":"96","author":"Liesker","year":"2002","journal-title":"Respir Med"},{"key":"10.1378\/chest.125.1.249_bib43","first-page":"A227","article-title":"SPIRIVA\u00ae (tiotropium) improves exercise tolerance in COPD [abstract]","volume":"165","author":"O'Donnell","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.125.1.249_bib44","first-page":"A265","article-title":"SPIRIVA\u00ae (tiotropium) reduces exertional dyspnea in COPD [abstract]","volume":"165","author":"O'Donnell","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.125.1.249_bib45","first-page":"1","article-title":"COPD exacerbations: causes, impacts and implications for management","volume":"18","author":"Jeffery","year":"2002","journal-title":"Eur Respir Rev"},{"key":"10.1378\/chest.125.1.249_bib46","doi-asserted-by":"crossref","first-page":"196","DOI":"10.7326\/0003-4819-106-2-196","article-title":"Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease","volume":"106","author":"Anthonisen","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.125.1.249_bib47","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1378\/chest.117.5_suppl_2.398S","article-title":"Toward a consensus definition for COPD exacerbations","volume":"117","author":"Rodriguez-Roisin","year":"2000","journal-title":"Chest"},{"key":"10.1378\/chest.125.1.249_bib48","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/bmj.320.7245.1297","article-title":"Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial","volume":"320","author":"Burge","year":"2000","journal-title":"BMJ"},{"key":"10.1378\/chest.125.1.249_bib49","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1164\/ajrccm\/145.6.1321","article-title":"A self-complete measure of health status for chronic airflow limitation: the St George's Respiratory Questionnaire","volume":"145","author":"Jones","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1378\/chest.125.1.249_bib50","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/thx.42.10.773","article-title":"A measure of quality of life for clinical trials in chronic lung disease","volume":"42","author":"Guyatt","year":"1987","journal-title":"Thorax"},{"key":"10.1378\/chest.125.1.249_bib51","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1183\/09031936.02.00063702","article-title":"Interpreting thresholds for a clinically significant change in health status in asthma and COPD","volume":"19","author":"Jones","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.125.1.249_bib52","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1378\/chest.114.2.411","article-title":"Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia","volume":"114","author":"Cazzola","year":"1998","journal-title":"Chest"},{"key":"10.1378\/chest.125.1.249_bib53","first-page":"CD001104","article-title":"Long-acting \u03b22-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation","volume":"3","author":"Appleton","year":"2002","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215318006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215318006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T18:27:19Z","timestamp":1682620039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369215318006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["S0012369215318006"],"URL":"https:\/\/doi.org\/10.1378\/chest.125.1.249","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}